MedTrace Logo

Cannabis for Spasticity in Multiple Sclerosis

NCT00682929 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-05-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary progressive multiple sclerosis.

Conditions

Interventions

DRUG

Inhaled Cannabis

Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.

DRUG

Oral THC

Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.

DRUG

Oral Placebo

Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.

DRUG

Inhaled placebo

Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.

Sponsors & Collaborators

  • National Multiple Sclerosis Society

    collaborator OTHER

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Michelle Apperson, MD, PhD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-14
Primary Completion
2011-08-17
Completion
2011-08-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00682929 on ClinicalTrials.gov